(Q42659855)

4 November 2017

title

Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib (English)

1 reference

4 November 2017

1 reference

1 reference

Peter C Trask

1

1 reference

4 November 2017

Andrew G Bushmakin

2

1 reference

4 November 2017

Joseph C Cappelleri

3

1 reference

4 November 2017

Paul Bycott

4

1 reference

4 November 2017

Katherine Liau

5

1 reference

4 November 2017

Sinil Kim

6

1 reference

4 November 2017

publication date

1 January 2008

1 reference

4 November 2017

1 reference

4 November 2017

volume

47

1 reference

4 November 2017

issue

5

1 reference

4 November 2017

page(s)

843-851

1 reference

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

Patient reported outcomes as endpoints in medical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

Interpreting the significance of changes in health-related quality-of-life scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802047395

10.1080/02841860802047395

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference